-->

Tag: Pembrolizumab HER2+ FDA approval

Home / Pembrolizumab HER2+ FDA approval

Categories

Pembrolizumab is approved by the USFDA for HER2 positive gastric or gastroesophageal junction adenocarcinoma expressing PD-L1 (CPS ≥1)

On March 19, 2025, the Food and Drug Administration officially approved pembrolizumab (Keytruda, Merck) to be used along with trastuzumab and chemotherapy that includes fluoropyrimidine and platinum f...
pembrolizumab-her2-fda-approval

Scan the code